Table 2.
Clinical features and treatment of late-onset neutropenia (LON) episodes.*
| Patients with LON – no. | 71 |
| LON episodes (initial + recurrent) – no. | 107 |
| Time to initial episode – months | 4.1 (1.6 - 23.1) |
| Nadir ANC – cells/μL | 490 (12 - 770) |
| Asymptomatic episodes | 700 (459 - 882) |
| Symptomatic episodes | 128 (11 - 420) |
| ALC at time of nadir ANC – cells/μL | 775 (504 - 1440) |
| Febrile neutropenia – no. episodes (%) | 30 (31.3) |
| Sepsis syndrome – no. episodes (%) | 8 (8.4) |
| Chief complaints – no. episodes (%) | |
| Asymptomatic/Incidental | 63 (59.4) |
| Fever | 30 (28.3) |
| Gum soreness | 4 (3.8) |
| Rash | 3 (2.8) |
| Fall | 1 (0.9) |
| Photophobia | 1 (0.9) |
| Productive cough | 1 (0.9) |
| Pain at tunneled catheter site | 1 (0.9) |
| Nausea/vomiting | 1 (0.9) |
| Malaise | 1 (0.9) |
| Source of infection – no. episodes (%) | |
| No apparent infection | 63 (65.0) |
| Gingivitis | 7 (7.2) |
| SSTI | 7 (7.2) |
| URI | 6 (6.2) |
| UTI | 5 (5.2) |
| GI (gastroenteritis or colitis) | 4 (4.1) |
| Pneumonia | 2 (2.1) |
| Conjunctivitis | 1 (1.0) |
| Bacteremia | 1 (1.0) |
| Vascular access catheter tunnel infection | 1 (1.0) |
| Prednisone dose at event - mg/day | 5 (0 - 12.5) |
| Serum IgG level at eventa - mg/dL | 557 (454 - 733) |
| Treatment of LON | |
| Antibiotic useb - no. episodes (%) | 34 (34.7) |
| Filgrastim use - no. episodes (%) | 70 (69.3) |
| Filgrastim use - doses/episode | 1 (1 - 2) |
| Duration of episode - days | 4 (3 - 7) |
*
Except where indicated otherwise, values are the median (interquartile range). Missing data excluded from calculations. ALC = absolute lymphocyte count; ANC = absolute neutrophil count; GI = gastrointestinal; IgG = immunoglobulin gamma; SSTI = skin and soft tissue infection; URI = upper respiratory infection; UTI = urinary tract infection.
a
Serum reference ranges (mg/dL): IgG 614 – 1295.
b
Therapeutic dosing.